CFR Chemaphor Inc.

Chemaphor Inc.(TSX VENTURE: CFR) At the recent Ontario Association of Veterinary Technicians (OAVT) Conference held in London, Ontario, about 1000 veterinary technicians were introduced to Avivagen Animal Health Inc. ("Avivagen") and its new products Oximunol™ Chewable Tablets and VetStem RC Regenerative Cell Therapy.

"Our participation in this tradeshow produced hundreds of leads from veterinary technicians interested in Oximunol™ Chewable Tablets and VetStem RC Regenerative Cell Therapy," said Kira Andersen, sales representative with Avivagen Animal Health. "We are going to be very busy following up with all those clinics in the coming weeks." About 250 technicians took time to talk at length with the Avivagen reps and sign up for a free draw for two pet baskets and a number of 50-day bottles of Oximunol™ Chewable Tablets to try on their own dogs.

"I am most definitely interested in trying Oximunol™ Chewable Tablets on my 15 year old Jack Russell after learning about it," said Nicole Swartzentruber, a registered veterinary technician with Embro Veterinary Services in Embro, Ontario. "If I see results in his mobility and overall health, I will definitely tell the veterinarians I work with about it."

The OAVT Conference was the first of numerous key tradeshows planned this year for Avivagen. Other major tradeshows booked include the American Animal Hospital Association/Ontario Veterinary Medical Association Conference in Toronto, ON, the Association des medecins veterinaries du Quebec, in Saint-Hyacinthe, QC, the Canadian Veterinary Medical Association Conference in Halifax, NS, the Animal Health Technologists Association of British Columbia Conference in Kamloops, BC and the CanWest Veterinary Conference in Banff, AB.

Oximunol™ Chewable Tablets contain OxC-beta, a fully oxidized form of ss-carotene, that is made up of compounds occurring naturally in the plant world. These compounds offer significant health benefits to dogs in a palatable, chewable daily tablet. Canadian clinical trials have shown a statistically significant improvement in coat quality, including a reduction of shedding. Oximunol™ Chewable Tablets also help dogs enjoy activity more and help optimize normal gastrointestinal and general health, especially in older and less active dogs.

VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of arthritic conditions, and joint and ligament injuries in dogs, cats and horses. The therapy uses regenerative cells derived from an animal's own adipose tissue. A small amount of fat tissue is extracted by the patient's veterinarian, and then couriered to Avivagen Animal Health's new, state-of-the-art, Canadian laboratory facility in Charlottetown, PEI. The cells are processed and counted, following stringent sterility and quality assurance guidelines. The doses required for immediate treatment are then returned to the veterinarian for injection into the patient, often within 48 hours of extraction. Extra doses are stored by Avivagen Animal Health for future treatments.

Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by Avivagen for the Canadian animal health market from Vet-Stem (USA).

Chemaphor is a publicly traded company listed on the (TSX VENTURE: CFR).

™ Trademark of Chemaphor Inc. VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Avivagen Animal Health Inc. David Hankinson CEO 902-825-9270 Chemaphor Inc. Graham Burton, PhD President and Co-Founder 613-990-0969 Investor Relations: Evolution Group Inc. Sylvain Archambault 514-448-4887 / Toll free: 866-703-4887 s.archambault@evolutiongrp.com www.evolutiongrp.com